Covered recipient · General Payments record
VLAD C RADULESCU
Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology
General Payments · PY2020–2025
$23,573.95
- Reported across 38 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $2,500.00 | 1 |
| Travel and Lodging | $1,273.97 | 6 |
| Food and Beverage | $544.47 | 9 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Octapharma USA, Inc. | $3,806.67 | 10 |
| Novo Nordisk AS | $240.63 | 2 |
| CHIESI USA, INC. | $159.51 | 2 |
| Genentech USA, Inc. | $80.39 | 1 |
| Genetix Biotherapeutics Inc | $31.24 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Chiesi USA, Inc. | $129.45 | 12/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1242165440 | CMS |
| Chiesi USA, Inc. | $30.06 | 12/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1242165442 | CMS |
| Genentech USA, Inc. | $80.39 | 06/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1211605861 | CMS |
| Genetix Biotherapeutics Inc | $31.24 | 12/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1246821546 | CMS |
| Novo Nordisk Inc | $125.00 | 06/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189141214 | CMS |
| Novo Nordisk Inc | $115.63 | 12/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188300261 | CMS |
| Octapharma USA, Inc. | $2,500.00 | 11/20/2025 | Honoraria | Undisputed | 06/30/2026 | 1245082375 | CMS |
| Octapharma USA, Inc. | $632.37 | 11/20/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1245082377 | CMS |
| Octapharma USA, Inc. | $268.22 | 11/20/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1245082379 | CMS |
| Octapharma USA, Inc. | $140.40 | 11/20/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1245082381 | CMS |
| Octapharma USA, Inc. | $112.28 | 11/20/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1245082383 | CMS |
| Octapharma USA, Inc. | $61.43 | 11/20/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1245082385 | CMS |
| Octapharma USA, Inc. | $59.27 | 11/20/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1245082387 | CMS |
| Octapharma USA, Inc. | $17.00 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1245082389 | CMS |
| Octapharma USA, Inc. | $8.70 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1245082391 | CMS |
| Octapharma USA, Inc. | $7.00 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1245082393 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2021, 2022, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.